Introduction
============

Acute coronary syndrome (ACS) is a well-established major cause of death and disability in both developed and developing countries.[@b1-cmc-10-2016-029],[@b2-cmc-10-2016-029] Primary percutaneous coronary intervention (P-PCI) has become the preferred reperfusion strategy in ST-elevation myocardial infarction (STEMI) when performed by an experienced team in a timely manner.[@b3-cmc-10-2016-029],[@b4-cmc-10-2016-029] P-PCI has been shown to be superior to fibrinolysis in reducing morbidity and mortality in STEMI.[@b5-cmc-10-2016-029] Approximately 40--65% of patients treated with P-PCI for STEMI have multivessel disease (MVD), which is an independent predictor of long-term mortality in these patients.[@b6-cmc-10-2016-029]--[@b8-cmc-10-2016-029] In previous registries, delayed complete revascularization (CR) appeared to confer a benefit, whereas other published observational studies have generally suggested that immediate CR is not only without benefit but may also be harmful.[@b9-cmc-10-2016-029],[@b10-cmc-10-2016-029] No consensus exists regarding the management of MVD detected at the time of P-PCI. Current guidelines recommend against performing PCI for nonculprit vessels at the time of P-PCI unless there is a hemodynamic instability.[@b11-cmc-10-2016-029],[@b12-cmc-10-2016-029] Various treatment strategies for nonculprit vessels have generated considerable interest and controversy. These include medical therapy and multivessel revascularization at the time of P-PCI and staged PCI. However, the achievement of CR is uncommon when treating ACS patients with multivessel coronary disease with PCI.[@b13-cmc-10-2016-029]

The SYNTAX score (SS) is an angiographic scoring tool for systematically quantifying the severity of each coronary lesion and assessing its individual characteristics.[@b14-cmc-10-2016-029] This scoring tool is used worldwide to predict long-term outcomes in patients with coronary artery disease (CAD) undergoing elective PCI or coronary artery bypass graft (CABG) surgery. The SS is also useful for predicting short- and long-term outcomes in patients with STEMI who are treated with P-PCI. The residual SYNTAX score (rSS) has been shown to be an independent predictor of one-year ischemic events in patients with medium- to high-risk ACS[@b13-cmc-10-2016-029] and of long-term adverse outcomes in patients with MVD undergoing PCI.[@b15-cmc-10-2016-029]

Aim
===

This study was designed to evaluate the use of the rSS following a complete vs. culprit-only revascularization strategy in patients with STEMI and MVD to quantify the extent and complexity of residual coronary stenoses and their impact on adverse ischemic outcomes.

Methods
=======

This single-center prospective study included 120 consecutive STEMI patients with angiographic patterns of multivessel CAD, with a baseline syntax score ≤22 and a clinical indication to undergo PCI according to the guidelines.[@b11-cmc-10-2016-029],[@b12-cmc-10-2016-029] Patients with a previous medical history of MI, CABG, or PCI and patients presenting with cardiogenic shock were excluded. The decision to undergo PCI was taken after "heart team" consultation. The included patients were divided into the following two groups: Group I: 60 patients with MVD undergoing PCI for a culprit-vessel only.Group II: 60 patients with MVD undergoing staged PCI for a culprit-vessel and another lesion in a staged procedure (within 5--30 days).

The decision to undergo culprit-only or staged PCI was based on the coronary anatomy, disease, age and comorbidities, patient's preference, operator's decision, and limited availability of staged intervention due to financial constraints in our country. The first 60 patients (in each group) who met the inclusion criteria/type of intervention were included.

Procedural Data
===============

All patients who underwent PCI received at least 300 mg of aspirin and a 600-mg loading dose of clopidogrel. Heparin was administered throughout the procedure to maintain an activated clotting time of ≥250 seconds. DES selection and glycoprotein IIb/IIIa inhibitors were used at the discretion of the operator. After the procedure, all the patients received 100 mg/day of aspirin indefinitely, as well as 150 mg for seven days and then 75 mg/day of clopidogrel for at least 12 months. Standard postintervention care was recommended.

Angiographic Analysis
=====================

Angiographic imaging was performed in two orthogonal views after an intracoronary injection of nitrates. Each lesion was measured before and after stenting on unoptically magnified cine angiographic frames, showing the lesion at its highest grade and using the guiding catheter as a reference. Measurements of the diameter of the guiding catheter, the minimal vessel lumen diameter, and the percent stenosis before and after stenting were performed by automatic contour edge detection; intravascular ultrasound imaging was not used routinely. The patients' angiography images were reviewed, and the SS and rSS were calculated by the same trained physician using a web-based calculator ([www.syntaxscore.com](http://www.syntaxscore.com)). The physician was blinded to the clinical outcomes of the patients. All of the parameters and stenoses were assessed visually. The rSS was determined as the SS remaining after completion of PCI. In the case of staged-PCI procedures (defined as a second planned PCI procedure after the initial intervention), the final planned procedure was used as the entry point for this study.

Patient Follow-up
=================

Clinical follow-up was conducted for all patients at 1, 3, 6, 9, and 12 months and every 3 months thereafter either during outpatient department visits or by direct telephone contact with the patients. All the patients were contacted for follow-up to assess the presence of angina and the occurrence of adverse events, such as death, nonfatal myocardial infarction, need for repeat percutaneous intervention in the target lesion, or CABG. For all patients who revealed cardiac symptoms, clinical evaluation was performed. Noninvasive testing for myocardial ischemia was conducted for all patients unless contraindicated at 12-month follow-up visit. Follow-up coronary angiography was performed in all patients with recurrent angina or positive noninvasive testing. All data collected were stored in a regularly updated computer database.

Study Outcomes and Definitions
==============================

The study outcome was a composite of major adverse cardiac events (MACE; a composite of cardiac death, MI, or ischemia-driven target lesion revascularization \[ID-TLR\]), death (cardiac and noncardiac), MI, ID-TLR, and stent thrombosis. Periprocedural MI was defined as an increase in the serum levels of creatine kinase-MB or creatine kinase three or more times the local upper limit of normal with preference given to creatine kinase-MB values or a persistent ST-segment elevation \>1 mm in two contiguous electrocardiographic limb leads or equal to 2 mm in two contiguous precordial leads. In patients who had increased creatine kinase or creatine kinase-MB at presentation, a diagnosis of MI required at least a twofold increase in enzyme levels after the procedure. Stent thrombosis was defined as definite or probable stent thrombosis according to the definitions of the Academic Research Consortium.[@b16-cmc-10-2016-029]

Statistical Analysis
====================

Count and percentage were used to describe and summarize the qualitative data. The arithmetic mean and standard deviation (SD) were used as measures of central tendency and dispersion, respectively, for the quantitative data. The quantitative data between the two groups were compared using the Student's *t*-test, while categorical variables were compared using the Pearson's chi-square test, and if \>20% of cells have expected cell count \<5, we used Fisher's exact test if 2 × 2 table and Monte Carlo significance test if more than 2 × 2 tables. Univariate analysis was conducted to determine factors related to the occurrence of Major Adverse Cardiac and Cerebrovascular Events (MACCE) at one year, and significant variables by univariate analysis were entered in a binary logistic regression model by enter method; odds ratio with 95% CI were calculated. All statistical analyses were performed using the SPSS software (version 20.0; SPSS, Inc.). A value of *P* \< 0.05 was considered statistically significant.

Ethics Statement
================

This study complied with the Declaration of Helsinki and was reviewed and approved by the ethics committee of the Faculty of Medicine, Alexandria University (review report serial number 0302694). All patients were informed about the technique and informed consents were obtained from them.

Results
=======

This study included 120 patients, 60 patients in the staged-PCI group and 60 patients in the culprit-vessel PCI group, from October 2012 to November 2013 at the International Cardiac Center and Alexandria Main University Hospital. The baseline characteristics of both the groups are presented in [Table 1](#t1-cmc-10-2016-029){ref-type="table"}.

There was no significant difference between the two groups with regard to the angiographic characteristics, baseline GRACE risk score, and baseline SS (20.07 ± 5.77 vs. 17.85 ± 6.84; *P* = 0.180), as shown in [Table 2](#t2-cmc-10-2016-029){ref-type="table"}. The mean total stent length (31.07 ± 12.7 mm vs. 76.3 ± 14.1 mm) and the number of stents implanted per patient (1.34 ± 0.6 vs. 2.47 ± 0.72) were higher in the staged-PCI groups. Angiographic and procedural data are shown in [Tables 2](#t2-cmc-10-2016-029){ref-type="table"} and [3](#t3-cmc-10-2016-029){ref-type="table"}, respectively.

Residual SYNTAX score
---------------------

The rSS in the culprit-vessel PCI group was significantly higher than that in the staged-PCI group: mean = 9.53 ± 5.32 vs. mean = 1.30 ± 1.99, respectively, and *P* \< 0.001 ([Table 3](#t3-cmc-10-2016-029){ref-type="table"}).

In-hospital outcome
-------------------

There was no significant difference in the in-hospital MACCE between both the groups (6.7% vs. 3.35%; *P* = 1.000). There was also no significant difference between both the groups with regard to minor and major bleeding complications, as shown in [Table 4](#t4-cmc-10-2016-029){ref-type="table"}.

Mid-term outcome
----------------

After a mean follow-up of 343 ± 75 days, the composite MACCE endpoint at one year (death, reinfarction, need for revascularization, and stroke) was higher in the culprit-vessel PCI group (16.66% vs. 5%; *P* = 0.04). In the culprit-vessel PCI group, four patients (6.7%) had reinfarction, seven patients (11.7%) underwent nontarget vessel revascularization, and four patients (6.7%) underwent target vessel revascularization (two patients had in-hospital cardiac arrest). In the staged-PCI group, MACCE was lower at one year, mainly due to significantly lower non-target vessel revascularization (3.33% vs. 18.3%; *P* = 0.008) during the follow-up period ([Table 4](#t4-cmc-10-2016-029){ref-type="table"}).

All patients treated by staged PCI (*n* = 60) and 24 patients in the culprit-vessel PCI group had an rSS \<8. Thirty six patients in the culprit-vessel PCI group had an rSS ≥8: 8 patients had total occlusion of one vessel and 28 patients had remaining stenosis (small vessel disease, distal vessel, or side branch); it should be noticed that the mean syntax score of this study population was ≤22. Comparing patients with an rSS \<8 (84 patients) with the remaining 36 patients in the culprit-vessel PCI group with an rSS ≥8, there were significant reductions in one-year MACCE (10.7% vs. 30.5%; *P* = 0.020), death/MI/CVA (5% vs. 13.9%; *P* = 0.016), and repeat revascularization (4.8% vs. 25%; *P* = 0.002; [Table 5](#t5-cmc-10-2016-029){ref-type="table"}). We found that the type of intervention (culprit-only), diabetes mellitus, intermediate/high GRACE risk score at discharge, and rSS ≥8 were independent predictors of MACCE at one year ([Table 6](#t6-cmc-10-2016-029){ref-type="table"}).

Discussion
==========

P-PCI is the standard of care for patients with STEMI. In up to 30% of such patients, significant stenoses are observed in one or more noninfarct-related arteries (N-IRA) during index angiography. The optimal management of patients found to have MVD, while undergoing P-PCI for STEMI remains unresolved.[@b1-cmc-10-2016-029]--[@b9-cmc-10-2016-029] The results of this study included 120 STEMI patients with MVD who were equally subdivided into two groups, those who underwent culprit-only and staged PCI, and found no significant difference in the occurrence of in-hospital MACCE between both the groups (6.7% vs. 3.35%; *P* = 0.492). However, the composite MACCE endpoint at one year (death, reinfarction, need for revascularization, and stroke) was higher in the culprit-vessel PCI group (16.66% vs. 6.66%; *P* = 0.014). When analyzing the outcomes according to the level of completeness of revascularization using the cutoff rSS ≤8, there were significant reductions in one-year MACCE (10.7% vs. 30.5%; *P* = 0.020), death/MI/CVA (5% vs. 13.9%, *P* = 0.016), and repeat revascularization (4.8% vs. 25%, *P* = 0.002). We found that the type of intervention (culprit-only), diabetes mellitus, intermediate/high GRACE risk score at discharge, and rSS ≥8 were independent predictors of MACCE at one year.

Recently, the Preventive Angioplasty in Acute Myocardial Infarction (PRAMI) trial reported that in patients with STEMI and multivessel CAD undergoing infarct artery PCI, preventive PCI in noninfarct coronary arteries with major stenoses significantly reduced ischemic events by \~65%, with CR during the index procedure.[@b17-cmc-10-2016-029] The results of the Complete Versus Lesion-Only Revascularization in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI and Multivessel Disease (CvLPRIT)[@b18-cmc-10-2016-029] were consistent with those observed in the PRAMI trial. CvLPRIT and PRAMI were similar in general design. Both assessed the safety and benefit of total revascularization intended around the time of P-PCI. CvLPRIT demonstrated that in a population of patients with STEMI treated by contemporary P-PCI, in-hospital CR of angiographically significant N-IRA lesions improved clinical outcomes compared with the treatment of culprit lesion only.

Prior meta-analyses of complete versus culprit-only revascularization for patients with MVD undergoing P-PCI for STEMI have reported varying results due to differences in study designs, comparisons of different groups, and different analytical methods.[@b19-cmc-10-2016-029]--[@b22-cmc-10-2016-029] Vlaar et al found that staged PCI resulted in lower short- and long-term mortality compared with MVD-PCI or IRA-PCI.[@b19-cmc-10-2016-029] Bangalore et al found that MVD-PCI compared with IRA-PCI resulted in similar long-term mortality, but a lower long-term rate of MACE.[@b20-cmc-10-2016-029] A recent meta-analysis demonstrated that MVD-PCI compared with IRA-PCI resulted in worse outcomes in cohort studies, but not in the randomized clinical trials.[@b21-cmc-10-2016-029] This is in line with our findings. Furthermore, Bainey et al found that staged-multivessel PCI was superior to multivessel PCI during the index procedure. The difference in outcome between the IRA-only and MVD-PCI groups may be due to revascularization, as differences in baseline may also play an important role.[@b22-cmc-10-2016-029] However, in real-world practice, CR in patients with STEMI and MVD is often not obtained.

Our results show that quantifying the extent and complexity of residual atherosclerosis after PCI can help to identify patients with MVD who are at increased risk for adverse long-term clinical outcomes. Our results are in parallel with the previous published data showing that an rSS \<8 is a suitable threshold for the definition of "reasonable" incomplete revascularization (ICR) and confirms the results of the SYNTAX trial.[@b13-cmc-10-2016-029]--[@b15-cmc-10-2016-029] Généreux et al reported that the 30-day and one-year rates of ischemic events were significantly higher in the ICR group, specifically in patients with moderate- and high-risk ACS undergoing PCI with an rSS \>8.[@b13-cmc-10-2016-029] Witberg et al studied 148 consecutive patients with triple-vessel/left main CAD treated by PCI. Patients with reasonable ICR (rSS \<8) had significant reductions in three-year MACCE and repeat revascularization.[@b23-cmc-10-2016-029] To date, the published trials and meta-analyses have been unable to define a comprehensive common strategy for all STEMI patients with MVD. Because these patients are very heterogeneous, any revascularization strategy should be individualized in this high-risk group of STEMI patients with impaired outcome related to the extent of CAD. However, the use of the available risk stratification scores and staged and ischemia-driven revascularization of the N-IRA with the achievement of "reasonable" CR may be the best treatment strategy for STEMI patients with MVD. The current ongoing COMPLETE and COMPARE ACUTE trials are studying these issues.

Conclusions
===========

Staged PCI that achieved reasonable CR (rSS ≤8) in patients with STEMI and MVD improved mid-term survival and reduced the need for repeat PCI. The rSS may improve the determination of an objective level of reasonable ICR. Such findings are of value in guiding the clinician to reduce the level of reversible myocardial ischemia by treating obstructive lesions in a manner that stays within the threshold of reasonable ICR. Nevertheless, large randomized trials are required to establish the optimal revascularization strategy for these high-risk patients.

Limitations
===========

This study was a prospective single-center study and therefore lacks randomization and intention to treat data. As an observational study, it is subject to selection bias. For example, patients may have been allocated to one treatment option because of the characteristics that would have made that option more preferable. Because of the limited sample size, the patients in our study might not be representative of the entire population of acute STEMI patients who undergo P-PCI. To confirm our findings, a study with a larger sample of patients is required. However, the results of our analysis should be considered hypothesis generating.
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###### 

Baseline clinical characteristics.

                                STAGED-PCI (n = 60)   CULPRIT ONLY (n = 60)   *P*                     
  ----------------------------- --------------------- ----------------------- --------------- ------- -------------------------------------------------------
  **Sex**                                                                                             
  Male                          44                    73.3                    50              83.3    0.161
  Female                        16                    26.7                    10              16.7    
  **Age**                                                                                             
  Mean ± SD                     56.7 ± 10.79                                  59.53 ± 10.86           0.326
  Hypertension                  30                    50                      28              46.7    0.715
  Diabetes                      26                    43.3                    28              46.7    0.174
  Smoking                       30                    50                      42              70      0.025[\*](#tfn1-cmc-10-2016-029){ref-type="table-fn"}
  Dyslipidemia                  24                    40.0                    36              60.0    0.028[\*](#tfn1-cmc-10-2016-029){ref-type="table-fn"}
  Family history of CAD         16                    26.7                    12              20.0    0.388
  **Chest pain to ER (min.)**                                                                         
  Mean ± SD                     241.5 ± 203.3                                 334.0 ± 298.4           0.101
  **Killip class**                                                                                    
  I                             54                    90.0                    56              93.3    0.509
  II                            6                     10.0                    4               6.7     
  **Pulse**                                                                                           
  Mean ± SD                     84.67 ± 14.74                                 82.90 ± 11.93           0.612
  **Systolic BP**                                                                                     
  Mean ± SD                     130.33 ±              21.73                   125.33 ±        23.15   0.392
  **Diastolic BP**                                                                                    
  Mean ± SD                     80.67 ± 13.18                                 80.0 ± 12.39            0.841
  **GRACE risk score**                                                                                
  Low                           36                    60                      26              43.3    0.079
  Intermediate                  20                    33.3                    32              53.3    
  High                          4                     6.7                     2               3.3     

**Notes:**

Statistically significant at *P* \< 0.05 by chi-square test. Age, pulse, systolic blood pressure (SBP), Diastolic blood pressure (DBP), and chest pain to Emergency Room (ER) were analyzed by the Student's *t*-test.

**Abbreviation:** MCP, Monte Carlo significance.

###### 

Baseline angiographic characteristics.

                                STAGED-PCI (n = 60)   CULPRIT ONLY (n = 60)   *P*              
  ----------------------------- --------------------- ----------------------- --------- ------ -------------------------------------------------------
  **No. of diseased vessels**                                                                  
  Two-vessel CAD                30                    50.0                    42        70.0   0.114
  Three-vessel CAD              30                    50.0                    18        30.0   
  **Culprit vessel**                                                                           
  LAD/diagonal                  42                    70.0                    26        43.3   0.037[\*](#tfn3-cmc-10-2016-029){ref-type="table-fn"}
  Ramus intermedius             0                     0.0                     2         3.3    1.000
  LCX/OM                        6                     10.0                    16        26.7   0.018[\*](#tfn3-cmc-10-2016-029){ref-type="table-fn"}
  RCA                           12                    20.0                    16        26.7   0.542
  Left main                     0                     0.0                     0         0.0    --
  **No. of lesions**                                                                           
  1                             52                    86.7                    48        80.0   0.672
  2                             6                     10.0                    10        16.7   
  3                             2                     3.3                     2         3.3    
  Thrombus containing lesion    26                    43.3                    26        43.3   1.000
  **TIMI flow grade pre-PCI**                                                                  
  0                             27                    45                      28        46.6   0.980
  I                             24                    40.0                    22        36.6   
  II                            5                     8.3                     6         10     
  III                           4                     6.6                     4         6.6    
  LVEF%                         50.50 ±               6.70                    51.43 ±   8.64   0.642
  Baseline SYNTAX score         20.07 ±               5.77                    17.85 ±   6.84   0.18

**Notes:**

Statistically significant at *P* \< 0.05 by chi-square test. left ventricular ejection fraction (LVEF)% and baseline syntax score were compared by the Student's *t*-test.

**Abbreviations:** FEP, Fisher's exact test significance; MCP, Monte Carlo significance test.

###### 

Procedural techniques, materials, and complications.

                                             STAGED-PCI (n = 60)   CULPRIT ONLY (n = 60)   *P*                     
  ------------------------------------------ --------------------- ----------------------- --------------- ------- ---------------------------------------------------------
  Door -to- balloon (min.)                   58.83 ± 25.92                                 72.67 ± 32.10           0.098
  GPIIb/IIIa Inhibitor (In hospital)         32                    53.3                    26              43.3    0.438
  Thrombus aspiration                        26                    43.3                    24              40      1.000
  Balloon pre-dilatation                     30                    50                      36              60.0    0.436
  Stent use                                  60                    100.0                   60              100.0   --
  Type of stent BMS                          0                     0                       2               3.3     0.792
  DES                                        60                    100                     58              96.6    
  Reference vessel diameter (mean ± SD)      3.13 ± 0.44                                   3.08 ± 0.36             0.630
  **Number of treated vessels**                                                                                    
  1-vessel                                   0                     0                       60              100     \<0.001[\*](#tfn5-cmc-10-2016-029){ref-type="table-fn"}
  2-vessel                                   36                    60                      0               0       
  3-vessel                                   24                    40                      0               0       
  **Number of stents implanted/pt**                                                                                
  1                                          0                     0                       54              90      \<0.001[\*](#tfn5-cmc-10-2016-029){ref-type="table-fn"}
  2                                          32                    53.33                   6               10      
  3                                          28                    46.66                   0               0       
  Number of stent implanted/pt (mean ± SD)   2.47 ± 0.72                                   1.34 ± 0.6              0.043[\*](#tfn5-cmc-10-2016-029){ref-type="table-fn"}
  Mean total stent length mm (mean ± SD)     76.3 ± 14.1                                   31.07 ± 12.7            \<0.001[\*](#tfn5-cmc-10-2016-029){ref-type="table-fn"}
  **TIMI flow grade pre-PCI**                                                                                      
  0                                          0                     0                       0               0       0.832
  I                                          0                     0                       0               0       
  II                                         1                     1.66                    6               10      
  III                                        59                    98.33                   60              100     
  **Residual SYNTAX score**                                                                                        
  Low (0--22)                                60                    100.0                   54              90.0    0.237
  Intermediate (23--32)                      0                     0.0                     6               10.0    
  High (\>32)                                0                     0.0                     0               0.0     
  Mean residual SYNTAX score                 1.30 ± 1.99                                   9.70 ± 5.70             \<0.001[\*](#tfn5-cmc-10-2016-029){ref-type="table-fn"}
  Procedure success                          58                    96.6                    56              93.3    0.679

**Notes:**

Statistically significant at *P* \< 0.05. Quantitative variables were compared by the Student's *t*-test.

**Abbreviations:** FEP, Fisher's exact test; MCP, Monte Carlo significance test.

###### 

In-hospital and mid-term outcomes.

                             STAGED-PCI (n = 60)   CULPRIT ONLY (n = 60))   *P*          
  -------------------------- --------------------- ------------------------ ----- ------ -------------------------------------------------------
  In-Hospital MACCE          3                     5                        4     6.7    1.000
  Death                      2                     3.33                     1     1.7    1.000
  Re-infarction              0                     0                        2     3.33   0.496
  TVR                        1                     1.7                      1     1.7    1.000
  Non TVR                    0                     0                        0     0      --
  Repeat revascularization   1                     1.66                     1     1.66   1.000
  Stroke                     0                     0                        0     0      --
  Death/MI/stroke            2                     3.33                     3     5.00   0.773
  Major bleeding             0                     0                        0     0      --
  Minor bleeding             2                     3.33                     0     0      0.487
  FU- MACCE(1-year)          6                     10                       14    23.3   0.040[\*](#tfn7-cmc-10-2016-029){ref-type="table-fn"}
  Death                      1                     1.7                      2     3.33   1.000
  Re-infarction              2                     3.33                     5     5.3    0.439
  TVR                        1                     1.7                      4     6.7    0.046[\*](#tfn7-cmc-10-2016-029){ref-type="table-fn"}
  Non TVR                    1                     1.66                     7     11.7   0.016[\*](#tfn7-cmc-10-2016-029){ref-type="table-fn"}
  Repeat revascularization   2                     3.33                     11    18.3   0.008
  Stroke                     0                     0                        0     0      --
  Death/MI/stroke            3                     5.00                     7     11.7   0.030[\*](#tfn7-cmc-10-2016-029){ref-type="table-fn"}

**Note:**

Statistically significant at *P* \< 0.05.

**Abbreviation:** FEP, Fisher's exact test.

###### 

Relationship between the rSS and one-year MACCE, repeated hospitalization, and angina.

                             RESIDUAL SYNTAX   *P*                
  -------------------------- ----------------- ------ ---- ------ ---------------------------------------------------------
  Repeated hospitalization   0                 0.0    12   33.3   \<0.001[\*](#tfn9-cmc-10-2016-029){ref-type="table-fn"}
  Angina                     0                 0.0    20   55.6   \<0.001[\*](#tfn9-cmc-10-2016-029){ref-type="table-fn"}
  MACCE(1-year)              9                 10.7   11   30.5   0.020[\*](#tfn9-cmc-10-2016-029){ref-type="table-fn"}
  Death                      1                 1.2    2    5.6    0.214
  Re-infarction              4                 4.8    3    8.3    0.427
  TVR                        1                 1.2    4    11.1   0.028[\*](#tfn9-cmc-10-2016-029){ref-type="table-fn"}
  Non TVR                    3                 3.6    5    13.8   0.025[\*](#tfn9-cmc-10-2016-029){ref-type="table-fn"}
  Repeat revascularization   4                 4.8    9    25     0.001[\*](#tfn9-cmc-10-2016-029){ref-type="table-fn"}
  Stroke                     0                 0      0    0      --
  Death/MI/stroke            5                 6      5    13.9   0.016[\*](#tfn9-cmc-10-2016-029){ref-type="table-fn"}

**Note:**

Statistically significant at *P* \< 0.05 by Fisher's exact test.

**Abbreviation:** FEP, Fisher's exact test.

###### 

Multivariate logistic regression model for the predictors of MACCE at one year.

                                        B        S.E.    WALD     ODDS RATIO   95% CI FOR OR   *P*-VALUE
  ------------------------------------- -------- ------- -------- ------------ --------------- ------------------------------------------------------------
  Type of intervention (culprit-only)   4.024    0.755   28.410   0.0180       0.004--0.079    \<0.001[\*\*](#tfn13-cmc-10-2016-029){ref-type="table-fn"}
  Diabetes Mellitus                     2.290    0.675   11.520   9.872        2.63--37.04     0.001[\*](#tfn12-cmc-10-2016-029){ref-type="table-fn"}
  GRACE score                                            10.616                                0.005[\*](#tfn12-cmc-10-2016-029){ref-type="table-fn"}
  GRACE score (Intermediate)            1.055    0.450   5.496    2.871        1.188--6.94     0.019[\*](#tfn12-cmc-10-2016-029){ref-type="table-fn"}
  GRACE score (High)                    2.843    1.043   7.426    17.172       2.222--132.7    0.006[\*](#tfn12-cmc-10-2016-029){ref-type="table-fn"}
  RSS ≥8                                −2.790   0.712   15.365   0.0610       0.015--0.245    \<0.001[\*\*](#tfn13-cmc-10-2016-029){ref-type="table-fn"}

**Notes:** Nagelkerke *R*^2^ = 0.73, Model *χ*^2^~(5)~ = 95.2, *P* \< 0.001.

*P* \< 0.05;

*P* \< 0.001. Reference categories intervention: staged PCI; DM: nondiabetic; GRACE score: low risk; rSS: \<8.
